ArticleBMC microbiology2025
Bacteriophage application in inhibiting corrosion- producing bacteria.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Staphylococcal phages as agents of evolution and innovation: From gene flow to next-generation therapeutics.Genetics and molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Sulfate-reducing bacteria (SRB) are a major cause of microbially-induced corrosion (MIC) and souring (MIS), leading to significant challenges in industries like oil recovery and wastewater treatment. Due to SRB's resistance to antimicrobial agents, bacteriophage (phage) therapy offers a promising alternative for SRB control. In this study, a novel lytic phage, SRB7757, targeting Desulfovibrio vulgaris, was isolated from sewage. SRB7757 inhibited sulfide production by 92.3% within 24 h and significantly reduced corrosion on metal specimens after 28 days, highlighting its potential in controlling MIC and MIS. Genome analysis revealed SRB7757 has a genome size of 142,573 bp, 217 ORFs, and 6 tRNAs, and belongs to the Chaseviridae family. SRB7757 exhibits a latent period of 4 h, a burst size of ~ 100 PFU/cell, and is stable between 4 °C and 60 °C across a pH range of 2.0-12.0. Two predicted lytic enzymes of SRB7757 demonstrated higher inactivation and biofilm removal rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.